CNMD CONMED Corp

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model centered on medical industry products and services, emphasizing talent attraction and retention amid intense competition
• • Suspension of quarterly dividend payments since October 2025 to extend share repurchase program, with future dividends uncertain due to financial and legal constraints
• • Anti-takeover provisions enhanced through board powers to issue preferred stock and procedural safeguards delaying change of control transactions
• • ESG regulatory compliance and corporate responsibility initiatives posing rising costs and risks, with potential fines, litigation, and reputational impact
• • No new products or segments introduced; focus on governance measures and evolving ESG landscape as distinctive 2026 filing themes

Risk Factors

• • Financial risk $840M long-term debt with $800M convertible notes due 2027 requiring incremental financing
• • Operational risk increased capital spending expected in 2026 funded by operating cash flow with monitored control
• • Market disruption risk share repurchase program $150M authorized, suspending dividends after $24.7M paid in 2025
• • Financial risk $61.4M contingent consideration payments due entirely within 1 year creating payment uncertainty
• • Financial risk revolving credit facility unused $648.5M availability with $40M term loan outstanding as of 12/31/25

Management Discussion & Analysis

• • Revenue $555M, flat YoY with orthopedic surgery and general surgery stable at 42% and 58% of sales respectively
• • Gross margin 48.3% vs 49.1% in prior year, reflecting inflationary cost pressures and supply chain challenges
• • Best segment: General surgery $321M, stable at 58% of sales; worst segment: Orthopedic surgery $234M, stable at 42% of sales
• • Capital allocation impacted by inflation with no specific buybacks, dividends, or capex disclosed in the section
• • Management engaged consultant in 2025 to improve manufacturing operations amid inflation, tariffs, and supply chain risks

What are the latest CNMD SEC filings in 2026?

CONMED Corp (CNMD) has filed a 10-K annual report on February 17, 2026, a 10-Q quarterly report on April 30, 2026, an 8-K current report on July 29, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did CNMD file its most recent 10-K annual report?

CONMED Corp (CNMD) filed its most recent 10-K annual report on February 17, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view CNMD 10-Q quarterly reports?

CONMED Corp (CNMD)'s most recent 10-Q quarterly report was filed on April 30, 2026. SignalX displays every CNMD 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has CNMD filed recently?

CONMED Corp (CNMD)'s most recent 8-K was filed on July 29, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find CNMD insider trading activity (Form 4)?

SignalX aggregates every CNMD Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does CNMD file with the SEC?

CONMED Corp (CNMD) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new CNMD filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for CONMED Corp (CNMD).

What is CNMD's SEC CIK number?

CONMED Corp (CNMD)'s SEC CIK (Central Index Key) number is 816956. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 816956 to look up all CNMD filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find CNMD return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from CONMED Corp (CNMD) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.